img

Global and United States Peptide CDMO Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Peptide CDMO Market Report & Forecast 2024-2034

Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis.
A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing.
CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
Market Analysis and InsightsGlobal and United States Peptide CDMO Market
This report focuses on global and United States Peptide CDMO market, also covers the segmentation data of other regions in regional level and county level.
The global Peptide CDMO revenue was US$ 3173.9 million in 2024 and is forecast to a readjusted size of US$ 8611.6 million by 2034 with a CAGR of 15.0% during the review period (2024-2034).
Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively. In terms of product categories, it is divided into APIs and intermediates and FDF, with the former holding the major market share of 67%. In terms of application, commercial is the top application area with a market share of 76%, followed by academic research institutions.
Global Peptide CDMO Scope and Market Size
Peptide CDMO market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Peptide CDMO market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2034.
For United States market, this report focuses on the Peptide CDMO market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.



By Company


Bachem
PolyPeptide
CordenPharma
AmbioPharm
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Xinbang Pharma
ScinoPharm
SN Biopharm
CBL
Piramal Pharma
CPC Scientific
Segment by Type
APIs and Intermediates
FDF

Segment by Application


Commercial
Academic Research
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Peptide CDMO definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Peptide CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Peptide CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide CDMO revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions

Table of Content

1 Study Coverage
1.1 Peptide CDMO Product Introduction
1.2 Global Peptide CDMO Outlook 2018 VS 2024 VS 2034
1.2.1 Global Peptide CDMO Market Size for the Year 2018-2034
1.2.2 United States Peptide CDMO Market Size for the Year 2018-2034
1.3 Peptide CDMO Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.3.1 The Market Share of United States Peptide CDMO in Global, 2018 VS 2024 VS 2034
1.3.2 The Growth Rate of Peptide CDMO Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.4 Peptide CDMO Market Dynamics
1.4.1 Peptide CDMO Industry Trends
1.4.2 Peptide CDMO Market Drivers
1.4.3 Peptide CDMO Market Challenges
1.4.4 Peptide CDMO Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Peptide CDMO by Type
2.1 Peptide CDMO Market Segment by Type
2.1.1 APIs and Intermediates
2.1.2 FDF
2.2 Global Peptide CDMO Market Size by Type (2018, 2024 & 2034)
2.3 Global Peptide CDMO Market Size by Type (2018-2034)
2.4 United States Peptide CDMO Market Size by Type (2018, 2024 & 2034)
2.5 United States Peptide CDMO Market Size by Type (2018-2034)
3 Peptide CDMO by Application
3.1 Peptide CDMO Market Segment by Application
3.1.1 Commercial
3.1.2 Academic Research
3.1.3 Other
3.2 Global Peptide CDMO Market Size by Application (2018, 2024 & 2034)
3.3 Global Peptide CDMO Market Size by Application (2018-2034)
3.4 United States Peptide CDMO Market Size by Application (2018, 2024 & 2034)
3.5 United States Peptide CDMO Market Size by Application (2018-2034)
4 Global Peptide CDMO Competitor Landscape by Company
4.1 Global Peptide CDMO Market Size by Company
4.1.1 Global Key Companies of Peptide CDMO, Ranked by Revenue (2024)
4.1.2 Global Peptide CDMO Revenue by Player (2018-2023)
4.2 Global Peptide CDMO Concentration Ratio (CR)
4.2.1 Peptide CDMO Market Concentration Ratio (CR) (2018-2023)
4.2.2 Global Top 5 and Top 10 Largest Companies of Peptide CDMO in 2024
4.2.3 Global Peptide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Peptide CDMO Head office and Area Served
4.4 Global Key Players of Peptide CDMO, Product and Application
4.5 Global Key Players of Peptide CDMO, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 United States Peptide CDMO Market Size by Company
4.7.1 Key Players of Peptide CDMO in United States, Ranked by Revenue (2024)
4.7.2 United States Peptide CDMO Revenue by Players (2021, 2024 & 2023)
5 Global Peptide CDMO Market Size by Region
5.1 Global Peptide CDMO Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Peptide CDMO Market Size by Region (2018-2034)
5.2.1 Global Peptide CDMO Market Size by Region: 2018-2023
5.2.2 Global Peptide CDMO Market Size by Region (2024-2034)
6 Americas
6.1 Americas Peptide CDMO Market Size YoY Growth 2018-2034
6.2 Americas Peptide CDMO Market Size by Type
6.2.1 Americas Peptide CDMO Market Size by Type (2018-2023)
6.2.2 Americas Peptide CDMO Market Size by Type (2024-2034)
6.2.3 Americas Peptide CDMO Market Share by Type (2018-2034)
6.3 Americas Peptide CDMO Market Size by Application
6.3.1 Americas Peptide CDMO Market Size by Application (2018-2023)
6.3.2 Americas Peptide CDMO Market Size by Application (2024-2034)
6.3.3 Americas Peptide CDMO Market Share by Application (2018-2034)
6.4 Americas Peptide CDMO Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Peptide CDMO Market Size YoY Growth 2018-2034
7.2 EMEA Peptide CDMO Market Size by Type
7.2.1 EMEA Peptide CDMO Market Size by Type (2018-2023)
7.2.2 EMEA Peptide CDMO Market Size by Type (2024-2034)
7.2.3 EMEA Peptide CDMO Market Share by Type (2018-2034)
7.3 EMEA Peptide CDMO Market Size by Application
7.3.1 EMEA Peptide CDMO Market Size by Application (2018-2023)
7.3.2 EMEA Peptide CDMO Market Size by Application (2024-2034)
7.3.3 EMEA Peptide CDMO Market Share by Application (2018-2034)
7.4 EMEA Peptide CDMO Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Peptide CDMO Market Size YoY Growth 2018-2034
8.2 China Peptide CDMO Market Size by Type
8.2.1 China Peptide CDMO Market Size by Type (2018-2023)
8.2.2 China Peptide CDMO Market Size by Type (2024-2034)
8.2.3 China Peptide CDMO Market Share by Type (2018-2034)
8.3 China Peptide CDMO Market Size by Application
8.3.1 China Peptide CDMO Market Size by Application (2018-2023)
8.3.2 China Peptide CDMO Market Size by Application (2024-2034)
8.3.3 China Peptide CDMO Market Share by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Peptide CDMO Market Size YoY Growth 2018-2034
9.2 APAC Peptide CDMO Market Size by Type
9.2.1 APAC Peptide CDMO Market Size by Type (2018-2023)
9.2.2 APAC Peptide CDMO Market Size by Type (2024-2034)
9.2.3 APAC Peptide CDMO Market Share by Type (2018-2034)
9.3 APAC Peptide CDMO Market Size by Application
9.3.1 APAC Peptide CDMO Market Size by Application (2018-2023)
9.3.2 APAC Peptide CDMO Market Size by Application (2024-2034)
9.3.3 APAC Peptide CDMO Market Share by Application (2018-2034)
9.4 APAC Peptide CDMO Market Facts & Figures by Country (2018, 2024 & 2034)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 Bachem
10.1.1 Bachem Company Details
10.1.2 Bachem Business Overview
10.1.3 Bachem Peptide CDMO Introduction
10.1.4 Bachem Revenue in Peptide CDMO Business (2018-2023)
10.1.5 Bachem Recent Development
10.2 PolyPeptide
10.2.1 PolyPeptide Company Details
10.2.2 PolyPeptide Business Overview
10.2.3 PolyPeptide Peptide CDMO Introduction
10.2.4 PolyPeptide Revenue in Peptide CDMO Business (2018-2023)
10.2.5 PolyPeptide Recent Development
10.3 CordenPharma
10.3.1 CordenPharma Company Details
10.3.2 CordenPharma Business Overview
10.3.3 CordenPharma Peptide CDMO Introduction
10.3.4 CordenPharma Revenue in Peptide CDMO Business (2018-2023)
10.3.5 CordenPharma Recent Development
10.4 AmbioPharm
10.4.1 AmbioPharm Company Details
10.4.2 AmbioPharm Business Overview
10.4.3 AmbioPharm Peptide CDMO Introduction
10.4.4 AmbioPharm Revenue in Peptide CDMO Business (2018-2023)
10.4.5 AmbioPharm Recent Development
10.5 USV Peptides
10.5.1 USV Peptides Company Details
10.5.2 USV Peptides Business Overview
10.5.3 USV Peptides Peptide CDMO Introduction
10.5.4 USV Peptides Revenue in Peptide CDMO Business (2018-2023)
10.5.5 USV Peptides Recent Development
10.6 Thermofischer
10.6.1 Thermofischer Company Details
10.6.2 Thermofischer Business Overview
10.6.3 Thermofischer Peptide CDMO Introduction
10.6.4 Thermofischer Revenue in Peptide CDMO Business (2018-2023)
10.6.5 Thermofischer Recent Development
10.7 Bio Basic
10.7.1 Bio Basic Company Details
10.7.2 Bio Basic Business Overview
10.7.3 Bio Basic Peptide CDMO Introduction
10.7.4 Bio Basic Revenue in Peptide CDMO Business (2018-2023)
10.7.5 Bio Basic Recent Development
10.8 JPT
10.8.1 JPT Company Details
10.8.2 JPT Business Overview
10.8.3 JPT Peptide CDMO Introduction
10.8.4 JPT Revenue in Peptide CDMO Business (2018-2023)
10.8.5 JPT Recent Development
10.9 Genscript
10.9.1 Genscript Company Details
10.9.2 Genscript Business Overview
10.9.3 Genscript Peptide CDMO Introduction
10.9.4 Genscript Revenue in Peptide CDMO Business (2018-2023)
10.9.5 Genscript Recent Development
10.10 Xinbang Pharma
10.10.1 Xinbang Pharma Company Details
10.10.2 Xinbang Pharma Business Overview
10.10.3 Xinbang Pharma Peptide CDMO Introduction
10.10.4 Xinbang Pharma Revenue in Peptide CDMO Business (2018-2023)
10.10.5 Xinbang Pharma Recent Development
10.11 ScinoPharm
10.11.1 ScinoPharm Company Details
10.11.2 ScinoPharm Business Overview
10.11.3 ScinoPharm Peptide CDMO Introduction
10.11.4 ScinoPharm Revenue in Peptide CDMO Business (2018-2023)
10.11.5 ScinoPharm Recent Development
10.12 SN Biopharm
10.12.1 SN Biopharm Company Details
10.12.2 SN Biopharm Business Overview
10.12.3 SN Biopharm Peptide CDMO Introduction
10.12.4 SN Biopharm Revenue in Peptide CDMO Business (2018-2023)
10.12.5 SN Biopharm Recent Development
10.13 CBL
10.13.1 CBL Company Details
10.13.2 CBL Business Overview
10.13.3 CBL Peptide CDMO Introduction
10.13.4 CBL Revenue in Peptide CDMO Business (2018-2023)
10.13.5 CBL Recent Development
10.14 Piramal Pharma
10.14.1 Piramal Pharma Company Details
10.14.2 Piramal Pharma Business Overview
10.14.3 Piramal Pharma Peptide CDMO Introduction
10.14.4 Piramal Pharma Revenue in Peptide CDMO Business (2018-2023)
10.14.5 Piramal Pharma Recent Development
10.15 CPC Scientific
10.15.1 CPC Scientific Company Details
10.15.2 CPC Scientific Business Overview
10.15.3 CPC Scientific Peptide CDMO Introduction
10.15.4 CPC Scientific Revenue in Peptide CDMO Business (2018-2023)
10.15.5 CPC Scientific Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details

List of Figure

List of Tables
Table 1. Peptide CDMO Market Size United States VS Global, CAGR (2018 VS 2024 VS 2034)
Table 2. Peptide CDMO Market Trends
Table 3. Peptide CDMO Market Drivers
Table 4. Peptide CDMO Market Challenges
Table 5. Peptide CDMO Market Restraints
Table 6. Global Peptide CDMO Market Size by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. United States Peptide CDMO Market Size by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Peptide CDMO Market Size by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. United States Peptide CDMO Market Size by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Companies of Peptide CDMO, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Peptide CDMO Revenue by Player, (US$ Million), 2018-2023
Table 12. Global Peptide CDMO Revenue Share by Player, 2018-2023
Table 13. Global Peptide CDMO Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Peptide CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO as of 2024)
Table 15. Global Key Players of Peptide CDMO, Headquarters and Area Served
Table 16. Global Key Players of Peptide CDMO, Product and Application
Table 17. Global Key Players of Peptide CDMO, Date of Enter into This Industry
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Key Players of Peptide CDMO in United States, Ranked by Revenue (2024) & (US$ Million)
Table 20. United States Peptide CDMO Revenue by Players, (US$ Million), 2021, 2024 & 2023
Table 21. United States Peptide CDMO Revenue Share by Players, 2021, 2024 & 2023
Table 22. Global Peptide CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 23. Global Peptide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 24. Global Peptide CDMO Market Size Forecast by Region (2024-2034) & (US$ Million)
Table 25. Americas Peptide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 26. Americas Peptide CDMO Market Size by Type (2024-2034) & (US$ Million)
Table 27. Americas Peptide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 28. Americas Peptide CDMO Market Size by Application (2024-2034) & (US$ Million)
Table 29. Americas Peptide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 30. Americas Peptide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 31. Americas Peptide CDMO Market Size by Country (2024-2034) & (US$ Million)
Table 32. EMEA Peptide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 33. EMEA Peptide CDMO Market Size by Type (2024-2034) & (US$ Million)
Table 34. EMEA Peptide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 35. EMEA Peptide CDMO Market Size by Application (2024-2034) & (US$ Million)
Table 36. EMEA Peptide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 37. EMEA Peptide CDMO Market Size by Country (2018-2023) & (US$ Million)
Table 38. EMEA Peptide CDMO Market Size by Country (2024-2034) & (US$ Million)
Table 39. China Peptide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 40. China Peptide CDMO Market Size by Type (2024-2034) & (US$ Million)
Table 41. China Peptide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 42. China Peptide CDMO Market Size by Application (2024-2034) & (US$ Million)
Table 43. China Peptide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 44. APAC Peptide CDMO Market Size by Type (2018-2023) & (US$ Million)
Table 45. APAC Peptide CDMO Market Size by Type (2024-2034) & (US$ Million)
Table 46. APAC Peptide CDMO Market Size by Application (2018-2023) & (US$ Million)
Table 47. APAC Peptide CDMO Market Size by Application (2024-2034) & (US$ Million)
Table 48. APAC Peptide CDMO Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 49. APAC Peptide CDMO Market Size by Region (2018-2023) & (US$ Million)
Table 50. APAC Peptide CDMO Market Size by Region (2024-2034) & (US$ Million)
Table 51. Bachem Company Details
Table 52. Bachem Business Overview
Table 53. Bachem Peptide CDMO Product
Table 54. Bachem Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 55. Bachem Recent Development
Table 56. PolyPeptide Company Details
Table 57. PolyPeptide Business Overview
Table 58. PolyPeptide Peptide CDMO Product
Table 59. PolyPeptide Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 60. PolyPeptide Recent Development
Table 61. CordenPharma Company Details
Table 62. CordenPharma Business Overview
Table 63. CordenPharma Peptide CDMO Product
Table 64. CordenPharma Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 65. CordenPharma Recent Development
Table 66. AmbioPharm Company Details
Table 67. AmbioPharm Business Overview
Table 68. AmbioPharm Peptide CDMO Product
Table 69. AmbioPharm Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 70. AmbioPharm Recent Development
Table 71. USV Peptides Company Details
Table 72. USV Peptides Business Overview
Table 73. USV Peptides Peptide CDMO Product
Table 74. USV Peptides Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 75. USV Peptides Recent Development
Table 76. Thermofischer Company Details
Table 77. Thermofischer Business Overview
Table 78. Thermofischer Peptide CDMO Product
Table 79. Thermofischer Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 80. Thermofischer Recent Development
Table 81. Bio Basic Company Details
Table 82. Bio Basic Business Overview
Table 83. Bio Basic Peptide CDMO Product
Table 84. Bio Basic Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 85. Bio Basic Recent Development
Table 86. JPT Company Details
Table 87. JPT Business Overview
Table 88. JPT Peptide CDMO Product
Table 89. JPT Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 90. JPT Recent Development
Table 91. Genscript Company Details
Table 92. Genscript Business Overview
Table 93. Genscript Peptide CDMO Product
Table 94. Genscript Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 95. Genscript Recent Development
Table 96. Xinbang Pharma Company Details
Table 97. Xinbang Pharma Business Overview
Table 98. Xinbang Pharma Peptide CDMO Product
Table 99. Xinbang Pharma Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 100. Xinbang Pharma Recent Development
Table 101. ScinoPharm Company Details
Table 102. ScinoPharm Business Overview
Table 103. ScinoPharm Peptide CDMO Product
Table 104. ScinoPharm Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 105. ScinoPharm Recent Development
Table 106. SN Biopharm Company Details
Table 107. SN Biopharm Business Overview
Table 108. SN Biopharm Peptide CDMO Product
Table 109. SN Biopharm Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 110. SN Biopharm Recent Development
Table 111. CBL Company Details
Table 112. CBL Business Overview
Table 113. CBL Peptide CDMO Product
Table 114. CBL Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 115. CBL Recent Development
Table 116. Piramal Pharma Company Details
Table 117. Piramal Pharma Business Overview
Table 118. Piramal Pharma Peptide CDMO Product
Table 119. Piramal Pharma Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 120. Piramal Pharma Recent Development
Table 121. CPC Scientific Company Details
Table 122. CPC Scientific Business Overview
Table 123. CPC Scientific Peptide CDMO Product
Table 124. CPC Scientific Revenue in Peptide CDMO Business (2018-2023) & (US$ Million)
Table 125. CPC Scientific Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide CDMO Product Picture
Figure 2. Global Peptide CDMO Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Peptide CDMO Market Size 2018-2034 (US$ Million)
Figure 4. United States Peptide CDMO Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 5. United States Peptide CDMO Market Size 2018-2034 (US$ Million)
Figure 6. United States Peptide CDMO Market Share in Global 2018-2034
Figure 7. Peptide CDMO Report Years Considered
Figure 8. Product Picture of APIs and Intermediates
Figure 9. Product Picture of FDF
Figure 10. Global Peptide CDMO Market Share by Type in 2024 & 2034
Figure 11. Global Peptide CDMO Market Size by Type (2018-2034) & (US$ Million)
Figure 12. Global Peptide CDMO Market Share by Type (2018-2034)
Figure 13. United States Peptide CDMO Market Share by Type in 2024 & 2034
Figure 14. United States Peptide CDMO Market Size by Type (2018-2034) & (US$ Million)
Figure 15. United States Peptide CDMO Market Share by Type (2018-2034)
Figure 16. Product Picture of Commercial
Figure 17. Product Picture of Academic Research
Figure 18. Product Picture of Other
Figure 19. Global Peptide CDMO Market Share by Application in 2024 & 2034
Figure 20. Global Peptide CDMO Market Size by Application (2018-2034) & (US$ Million)
Figure 21. Global Peptide CDMO Market Share by Application (2018-2034)
Figure 22. United States Peptide CDMO Market Share by Application in 2024 & 2034
Figure 23. United States Peptide CDMO Market Size by Application (2018-2034) & (US$ Million)
Figure 24. United States Peptide CDMO Market Share by Application (2018-2034)
Figure 25. The Top 5 and 10 Largest Companies of Peptide CDMO in the World: Market Share by Peptide CDMO Revenue in 2024
Figure 26. Global Peptide CDMO Market Size Market Share by Region: 2018 VS 2024 VS 2034
Figure 27. Global Peptide CDMO Market Share by Region (2018-2034)
Figure 28. Americas Peptide CDMO Market Size Growth Rate 2018-2034 (US$ Million)
Figure 29. Americas Peptide CDMO Market Share by Type (2018-2034)
Figure 30. Americas Peptide CDMO Market Share by Application (2018-2034)
Figure 31. United States Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 32. Canada Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 33. Mexico Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 34. Brazil Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 35. EMEA Peptide CDMO Market Size Growth Rate 2018-2034 (US$ Million)
Figure 36. EMEA Peptide CDMO Market Share by Type (2018-2034)
Figure 37. EMEA Peptide CDMO Market Share by Application (2018-2034)
Figure 38. Europe Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 39. Middle East Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 40. Africa Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 41. China Peptide CDMO Market Size Growth Rate 2018-2034 (US$ Million)
Figure 42. China Peptide CDMO Market Share by Type (2018-2034)
Figure 43. China Peptide CDMO Market Share by Application (2018-2034)
Figure 44. APAC Peptide CDMO Market Size Growth Rate 2018-2034 (US$ Million)
Figure 45. APAC Peptide CDMO Market Share by Type (2018-2034)
Figure 46. APAC Peptide CDMO Market Share by Application (2018-2034)
Figure 47. Japan Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 48. South Korea Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 49. China Taiwan Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 50. Southeast Asia Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 51. India Peptide CDMO Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 52. Bachem Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 53. PolyPeptide Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 54. CordenPharma Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 55. AmbioPharm Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 56. USV Peptides Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 57. Thermofischer Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 58. Bio Basic Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 59. JPT Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 60. Genscript Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 61. Xinbang Pharma Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 62. ScinoPharm Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 63. SN Biopharm Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 64. CBL Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 65. Piramal Pharma Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 66. CPC Scientific Revenue Growth Rate in Peptide CDMO Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed